Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment for Advanced Acral Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial
JAMA Oncol 2023 Jun 01;[EPub Ahead of Print], L Mao, B Lian, C Li, X Bai, L Zhou, C Cui, Z Chi, X Sheng, X Wang, B Tang, X Yan, S Li, Y Kong, J Dai, X Wei, J Li, R Duan, H Xu, X Wu, Y Yang, F Cheng, C Zhang, F Xia, Z Pang, J Guo, L SiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.